-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Initiates Coverage On Syndax Pharmaceuticals with Buy Rating, Announces Price Target of $18

Benzinga·07/10/2025 12:51:24
Listen to the news
Goldman Sachs analyst Corinne Johnson initiates coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy rating and announces Price Target of $18.